

Jean-Claude Tardif

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6319841/jean-claude-tardif-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

15,880
citations

49
h-index

125
g-index

206
ext. papers

19,964
ext. citations

10.4
avg, IF

6.33
L-index

#	Paper	IF	Citations
185	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS Score: Insights From the BRAIN-AF Trial.. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022 , CIRCEP121010462	6.4	0
184	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities.. <i>European Journal of Preventive Cardiology</i> , 2022 , 28, 1795-1806	3.9	0
183	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.. <i>Journal of the American Heart Association</i> , 2022 , e022937	6	3
182	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024999	6	0
181	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.. <i>Journal of the American Heart Association</i> , 2022 , e021327	6	1
180	Protein tyrosine phosphatase 1B regulates miR-208b-argonaute 2 association and thyroid hormone responsiveness in cardiac hypertrophy.. <i>Science Signaling</i> , 2022 , 15, eabn6875	8.8	0
179	Colchicine in Cardiovascular Disease: In-Depth Review.. <i>Circulation</i> , 2022 , 145, 61-78	16.7	4
178	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1660-1671	15.1	7
177	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 486-495	4.6	18
176	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 812018	5.6	1
175	Hair cortisol change at COVID-19 pandemic onset predicts burnout among health personnel.. <i>Psychoneuroendocrinology</i> , 2021 , 138, 105645	5	0
174	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1525-1537	15.1	6
173	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <i>Circulation</i> , 2021 , 144, 1845-1855	16.7	10
172	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. <i>Circulation</i> , 2021 , 144, 1750-1759	16.7	8
171	Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 776-785	3.8	27
170	The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. <i>Cardiovascular Research</i> , 2021 , 117, 1776-1789	9.9	13
169	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021 , 42, 1742-1756	9.5	20

168	Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women. <i>Pharmacogenomics Journal</i> , 2021 , 21, 446-457	3.5	1
167	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003183	5.2	2
166	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003219	5.2	0
165	ApoA-I mimetic does not improve left ventricular diastolic dysfunction in rabbits without aortic valve stenosis. <i>International Journal of Cardiology</i> , 2021 , 331, 199-205	3.2	
164	Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 3107-3121	9.3	6
163	Racial Disparities in Acute Coronary Syndrome Management Within a Universal Healthcare Context: Insights From the AMI-OPTIMA Trial.. <i>CJC Open</i> , 2021 , 3, S28-S35	2	0
162	Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodelling. <i>Cardiovascular Research</i> , 2021 , 117, 462-471	9.9	10
161	Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. <i>Circulation</i> , 2021 , 143, 33-44	16.7	25
160	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e61-e63	6.4	9
159	Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e891-e898	5.6	3
158	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 287-294	4.6	1
157	Repurposing colchicine's journey in view of drug-to-drug interactions. A review. <i>Toxicology Reports</i> , 2021 , 8, 1389-1393	4.8	1
156	Initiation of low-dose colchicine early after myocardial infarction. <i>European Heart Journal</i> , 2021 , 42, 2798-2799	9.3	1
155	Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. <i>Pharmacotherapy</i> , 2021 , 41, 379-393	5.8	0
154	Colchicine in the Management of Acute and Chronic Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2021 , 23, 120	4.2	0
153	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 1837-1845	3.8	1
152	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. <i>Circulation</i> , 2021 , 144, 512-523	16.7	6
151	Association of Atrial Fibrillation Burden With Health-Related Quality of Life After Atrial Fibrillation Ablation: Substudy of the Cryoballoon vs Contact-Force Atrial Fibrillation Ablation (CIRCA-DOSE) Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1324-1328	16.2	8

150	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. <i>Nature Genetics</i> , 2021 , 53, 128-134	36.3	35
149	Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease. <i>European Heart Journal</i> , 2021 , 42, 2800-2801	9.5	3
148	High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2020 , 4, 2430-2438	7.8	22
147	Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. <i>European Heart Journal</i> , 2020 , 41, 2974-2982	9.5	82
146	Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320918728	3.9	8
145	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. <i>PLoS ONE</i> , 2020 , 15, e0242318	3.7	13
144	Knockdown of ANGPTL2 promotes cardiac left ventricular dysfunction in mice via up-regulation of NOX4. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
143	REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. <i>Circulation</i> , 2020 , 141, 367-375	16.7	67
142	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2020 , 382, 244-255	59.2	265
141	Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. <i>Pharmacotherapy</i> , 2020 , 40, 40-54	5.8	43
140	The Polygenic and Monogenic Basis of Blood Traits and Diseases. <i>Cell</i> , 2020 , 182, 1214-1231.e11	56.2	96
139	Comparison of Atrial Remodeling Caused by Sustained Atrial Flutter Versus Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 374-388	15.1	9
138	Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. <i>Cell</i> , 2020 , 182, 1198-1213.e14	56.2	88
137	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 426-436	3.9	9
136	Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2020 , 21, 692-700	4.1	5
135	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020 , 41, 347-356	9.5	20
134	A genetic model of ivabradine recapitulates results from randomized clinical trials 2020 , 15, e0236193		
133	A genetic model of ivabradine recapitulates results from randomized clinical trials 2020 , 15, e0236193		

132	A genetic model of ivabradine recapitulates results from randomized clinical trials 2020 , 15, e0236193		
131	A genetic model of ivabradine recapitulates results from randomized clinical trials 2020 , 15, e0236193		
130	Colchicine reduces lung injury in experimental acute respiratory distress syndrome 2020 , 15, e0242318		
129	Colchicine reduces lung injury in experimental acute respiratory distress syndrome 2020 , 15, e0242318		
128	Colchicine reduces lung injury in experimental acute respiratory distress syndrome 2020 , 15, e0242318		
127	Colchicine reduces lung injury in experimental acute respiratory distress syndrome 2020 , 15, e0242318		
126	Right Atrial Mechanisms of Atrial Fibrillation in a Rat Model of Right Heart Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1332-1347	15.1	28
125	An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation. <i>Cardiovascular Research</i> , 2019 , 115, 1975-1985	9.9	8
124	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2791-2802	15.1	152
123	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 1069-1077	3.8	16
122	MK5 haplodeficiency decreases collagen deposition and scar size during post-myocardial infarction wound repair. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019 , 316, H1281-H1296	5.2	5
121	Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling. <i>Cardiovascular Research</i> , 2019 , 115, 94-106	9.9	21
120	Cardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits. <i>PLoS ONE</i> , 2019 , 14, e0220707	3.7	4
119	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1159-1161	15.1	52
118	Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies. <i>BMC Medicine</i> , 2019 , 17, 197	11.4	18
117	Mice knockdown for angiotensin-like 2 spontaneously develop aortic valve stenosis. <i>FASEB Journal</i> , 2019 , 33, 120.4	0.9	
116	Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1362-1364	15.1	27
115	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019 , 381, 2497-2505	59.2	861

114	Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 1059-1079	5.9	1
113	From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants. <i>Current Opinion in Lipidology</i> , 2019 , 30, 101-107	4.4	15
112	Blood pressure and burden of hypertension in Cameroon, a microcosm of Africa: a systematic review and meta-analysis of population-based studies. <i>Journal of Hypertension</i> , 2019 , 37, 2190-2199	1.9	14
111	β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. <i>European Heart Journal</i> , 2019 , 40, 1399-1407	9.5	35
110	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2019 , 380, 11-22	59.2	1316
109	Exome Chip Meta-analysis Fine Maps Causal Variants and Elucidates the Genetic Architecture of Rare Coding Variants in Smoking and Alcohol Use. <i>Biological Psychiatry</i> , 2019 , 85, 946-955	7.9	35
108	ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein). <i>Circulation</i> , 2018 , 138, 1677-1692	16.7	16
107	Perioperative THR-184 and AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 670-679	12.7	20
106	A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure. <i>Pharmacogenomics</i> , 2018 , 19, 599-612	2.6	5
105	Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. <i>European Heart Journal</i> , 2018 , 39, 4150-4158	9.5	49
104	Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. <i>Hypertension</i> , 2018 , 71, 168-176	8.5	30
103	Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. <i>European Heart Journal</i> , 2018 , 39, 3855-3863	9.5	15
102	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 244-256	6.1	8
101	CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 396-400	9.4	24
100	Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]). <i>Circulation</i> , 2017 , 135, 1788-1798	16.7	47
99	MK5 haplodeficiency attenuates hypertrophy and preserves diastolic function during remodeling induced by chronic pressure overload in the mouse heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017 , 313, H46-H58	5.2	11
98	Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys. <i>Journal of Lipid Research</i> , 2017 , 58, 1282-1291	6.3	9
97	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	45

96	Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. <i>Clinical Cardiology</i> , 2017 , 40, 797-806	3.3	29
95	Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). <i>Circulation</i> , 2017 , 135, 2320-2332	16.7	196
94	Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. <i>Clinical Cardiology</i> , 2017 , 40, 138-148	3.3	114
93	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017 , 376, 1517-1526	59.2	226
92	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017 , 376, 1527-1539	59.2	390
91	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2017 , 22, 1-26	3.7	31
90	Precision medicine to change the landscape of cardiovascular drug development. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 337-343	1.6	
89	Apolipoprotein A-I Modulates Atherosclerosis Through Lymphatic Vessel-Dependent Mechanisms in Mice. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	17
88	Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targeting and Statin Therapies. <i>Current Atherosclerosis Reports</i> , 2017 , 19, 43	6	6
87	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017 , 136, 1560-1562	16.7	5
86	Impact of hyperventilation and apnea on myocardial oxygenation in patients with obstructive sleep apnea - An oxygenation-sensitive CMR study. <i>Journal of Cardiology</i> , 2017 , 69, 489-494	3	11
85	Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 81-90	2.6	3
84	Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome. <i>PLoS ONE</i> , 2017 , 12, e0168448	3.7	7
83	Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies. <i>JMIR Research Protocols</i> , 2017 , 6, e102	2	5
82	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. <i>Lancet, The</i> , 2016 , 388, 2142-2152	40	261
81	A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. <i>Canadian Journal of Anaesthesia</i> , 2016 , 63, 1140-53	3	52
80	Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 340-8		47
79	Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 2439-2445	9.4	130

78	Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1769-1780	15.1	59
77	The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy. <i>Biomarkers in Cancer</i> , 2016 , 8, 39-45	7	29
76	Rationale, design, and methods for Canadian alliance for healthy hearts and minds cohort study (CAHHM) - a Pan Canadian cohort study. <i>BMC Public Health</i> , 2016 , 16, 650	4.1	24
75	Pharmacogenomic approaches to lipid-regulating trials. <i>Current Opinion in Lipidology</i> , 2016 , 27, 557-562	4.4	4
74	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , 2016 , 99, 40-55	11	61
73	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , 2016 , 99, 22-39	11	42
72	Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 59-64	3.9	6
71	Resting heart rate as a predictor of aortic valve stenosis progression. <i>International Journal of Cardiology</i> , 2016 , 204, 149-51	3.2	8
70	Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 344-6	15.1	26
69	Ivabradine for the treatment of chronic heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 553-61	2.5	3
68	Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016 , 9, 31-8	5.8	11
67	Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 676-84	1.9	6
66	Whole-genome sequencing in French Canadians from Quebec. <i>Human Genetics</i> , 2016 , 135, 1213-1221	6.3	13
65	Ivabradine and metoprolol differentially affect cardiac glucose metabolism despite similar heart rate reduction in a mouse model of dyslipidemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016 , 311, H991-H1003	5.2	8
64	HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits. <i>International Journal of Cardiology</i> , 2016 , 215, 364-71	3.2	8
63	Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 1134-44	59.2	325
62	Cardiometabolic and traditional cardiovascular risk factors and their potential impact on macrovascular and microvascular function: preliminary data. <i>Clinical Hemorheology and Microcirculation</i> , 2015 , 59, 53-65	2.5	21
61	Loss of cardiomyocyte integrin-linked kinase produces an arrhythmogenic cardiomyopathy in mice. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015 , 8, 921-32	6.4	14

60	Novel anti-inflammatory therapies for the treatment of atherosclerosis. <i>Atherosclerosis</i> , 2015 , 240, 497-509	509	97
59	A numerical investigation of the functionality of coronary bifurcation lesions with respect to lesion configuration and stenosis severity. <i>Journal of Biomechanics</i> , 2015 , 48, 3103-11	2.9	11
58	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015 , 373, 2247-57	59.2	1393
57	Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 812-22		42
56	Acute intraoperative effect of intravenous amiodarone on right ventricular function in patients undergoing valvular surgery. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 316-25	4.3	3
55	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. <i>PLoS Genetics</i> , 2015 , 11, e1005378	6	220
54	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
53	Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 372-82		119
52	Expression of phosphoinositide-specific phospholipase C isoforms in native endothelial cells. <i>PLoS ONE</i> , 2015 , 10, e0123769	3.7	12
51	The relation between hostility and concurrent levels of inflammation is sex, age, and measure dependent. <i>Journal of Psychosomatic Research</i> , 2014 , 76, 384-93	4.1	19
50	Aortic coarctation and the retinal microvasculature. <i>International Journal of Cardiology</i> , 2014 , 174, 25-30.	3.2	4
49	Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2013-23	15.1	128
48	Detailed characterization of microRNA changes in a canine heart failure model: Relationship to arrhythmogenic structural remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 77, 113-24	5.8	36
47	Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: potential significance in arrhythmogenesis and antiarrhythmic therapy. <i>Heart Rhythm</i> , 2014 , 11, 2092-100	6.7	20
46	Ivabradine in stable coronary artery disease without clinical heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 1091-9	59.2	315
45	Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1441-8	15.1	62
44	The interleukin-1 β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. <i>Atherosclerosis</i> , 2014 , 236, 277-85	3.1	11
43	CKM and LILRB5 are associated with serum levels of creatine kinase. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 880-6		26

42	Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits. <i>Nature Genetics</i> , 2014 , 46, 629-34	36.3	92
41	Circulating levels of linoleic acid and HDL-cholesterol are major determinants of 4-hydroxynonenal protein adducts in patients with heart failure. <i>Redox Biology</i> , 2014 , 2, 148-55	11.3	20
40	Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 837-49	3.8	97
39	Optimisation of reference genes for gene-expression analysis in a rabbit model of left ventricular diastolic dysfunction. <i>PLoS ONE</i> , 2014 , 9, e89331	3.7	7
38	Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes. <i>Circulation: Heart Failure</i> , 2014 , 7, 773-81	7.6	33
37	Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. <i>JAMA Internal Medicine</i> , 2014 , 174, 1651-9	11.5	84
36	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nature Communications</i> , 2014 , 5, 5068	17.4	160
35	Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. <i>Circulation: Cardiovascular Genetics</i> , 2014 , 7, 304-10		160
34	Nonsense mutations in BAG3 are associated with early-onset dilated cardiomyopathy in French Canadians. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1655-61	3.8	43
33	A look into the future of cardiology: perspectives from the Montreal Heart Institute. <i>Canadian Journal of Cardiology</i> , 2014 , 30, S399-400	3.8	
32	Validation of patient-reported warfarin dose in a prospective incident cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 285-9	2.6	4
31	Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2048-55	15.1	129
30	Effects of dalcetrapib in patients with a recent acute coronary syndrome. <i>New England Journal of Medicine</i> , 2012 , 367, 2089-99	59.2	1424
29	Imaging biomarkers in atherosclerosis trials. <i>Circulation: Cardiovascular Imaging</i> , 2011 , 4, 319-33	3.9	50
28	Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. <i>Circulation: Cardiovascular Imaging</i> , 2010 , 3, 298-307	3.9	105
27	A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010 , 3, 543-8	6	54
26	Coronary artery disease in 2010. <i>European Heart Journal Supplements</i> , 2010 , 12, C2-C10	1.5	16
25	Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?. <i>Journal of Clinical Lipidology</i> , 2010 , 4, 399-404	4.9	31

24	Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. <i>European Heart Journal</i> , 2009 , 30, 540-8	9.5	241
23	High-density lipoprotein/apolipoprotein A-I infusion therapy. <i>Current Atherosclerosis Reports</i> , 2009 , 11, 58-63	6	35
22	Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009 , 158, 896-901.e3	4.9	166
21	Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 371, 1761-8	4.0	149
20	The pivotal role of heart rate in clinical practice: from atherosclerosis to acute coronary syndrome. <i>European Heart Journal Supplements</i> , 2008 , 10, F11-F16	1.5	0
19	A survey of the personalized medicine landscape. <i>Pharmacogenomics</i> , 2008 , 9, 819-823	2.6	1
18	Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovanage 4). <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2008 , 15, e177-87	2	1
17	Effects of torcetrapib in patients at high risk for coronary events. <i>New England Journal of Medicine</i> , 2007 , 357, 2109-22	59.2	2323
16	Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1675-82	27.4	560
15	Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound. <i>American Journal of Cardiology</i> , 2006 , 98, 23-7	3	23
14	Can ACAT inhibition limit the progression of atherosclerosis in patients with coronary artery disease?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006 , 3, 366-7		1
13	Cardiac investigation in patients with diabetes. <i>Canadian Journal of Cardiology</i> , 2006 , 22 Suppl A, 38A-40A		38
12	Atherosclerosis imaging. <i>Canadian Journal of Cardiology</i> , 2005 , 21, 1035-9	3.8	3
11	Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. <i>Circulation</i> , 2004 , 109, 412-8	16.7	154
10	Effect of inhibition of the Na ⁺ /H ⁺ exchanger with cariporide on left ventricular function in acute coronary syndromes: results from the echocardiographic substudy of the GUARDIAN trial. <i>Canadian Journal of Cardiology</i> , 2004 , 20, 317-22	3.8	9
9	Clinical results with AGI-1067: a novel antioxidant vascular protectant. <i>American Journal of Cardiology</i> , 2003 , 91, 41A-49A	3	30
8	Prevention of restenosis with antioxidants: mechanisms and implications. <i>American Journal of Cardiovascular Drugs</i> , 2002 , 2, 323-34	4	48
7	Pulsatile hemodynamics in congestive heart failure. <i>Hypertension</i> , 2001 , 38, 1433-9	8.5	158

6	Atrioventricular interval optimization and exercise tolerance. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001 , 24, 1534-40	1.6	26
5	Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. <i>Circulation</i> , 1999 , 99, 30-5	16.7	125
4	Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. <i>Circulation</i> , 1999 , 99, 3227-33	16.7	433
3	Transvenous catheter ice mapping and cryoablation of the atrioventricular node in dogs. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1999 , 22, 1488-98	1.6	112
2	The Polygenic and Monogenic Basis of Blood Traits and Diseases		3
1	Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19		34